chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Chronic%20myeloid%20leukemia Treatment

Principles of Therapy

  • In general, the choice of first-line therapy may depend on risk score, physician's experience, age, ability to tolerate therapy and comorbid conditions
  • TKIs are recommended 1st-line therapy for patients with CP-CML and AP-CML
    • Both 1st and 2nd generation TKIs are recommended as primary treatment for newly diagnosed low-risk CP-CML patients
    • Second generation TKIs Dasatinib, Nilotinib and Bosutinib are recommended for newly diagnosed CP-CML patients with intermediate- to high-risk
      • First-generation TKI Imatinib was previously recommended as 1st-line treatment for CML patients with intermediate- to high-risk but with the emergence of 2nd generation TKIs, these are now preferred over Imatinib therapy
      • Studies showed that Bosutinib, Dasatinib and Nilotinib possess higher major molecular response (MMR) rate and deeper molecular responses compared to Imatinib
    • Dasatinib or Bosutinib are preferred TKIs for CP-CML patients with history of arrhythmia, cardiac disorders, pancreatitis, or increased blood glucose
    • For CP-CML patients with pulmonary disorders and those at increased risk for pleural effusion, Nilotinib or Bosutinib are preferred
  • For patients with disease progression despite previous monotherapy with TKI, an alternate TKI not previously given may be considered
  • Omacetaxine therapy or Allo-HCT may be considered for AP-CML patients unresponsive to multi-TKI therapy
  • Allo-HCT is the recommended 1st-line treatment option for newly-diagnosed BP-CML patients

Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy

  • Predicts the achievement of complete molecular response (CMR) on standard-dose Imatinib
  • The marker that identifies a non-adherent CP-CML patient is the BCR-ABL1 doubling time
  • Educate the patient on their adherence to tyrosine kinase inhibitor therapy and monitor them closely
  • Non-adherence may result to poorer treatment response that can result to loss of major molecular response, hematologic failure, cytogenic relapse and treatment failure
  • Appropriate management of the side effects will improve patient adherence

Discontinuation of TKI Therapy

  • May be considered if all of the criteria are present
  • Criteria for discontinuation of TKI therapy include:
    • Patient aged ≥18 years old
    • Disease in chronic phase without any history of accelerated or blast phase
    • At least 3 years of TKI therapy
    • Presence of BCR-ABL1 transcripts at time of diagnosis-
    • 2 years of stable molecular response (BCR-ABL1 ≤0.01% IS) for ≥2 years in at least 4 tests obtained ≥3 months apart
    • Reliable qPCR test (MR4.5 and BCR-ABL1 ≤0.0032% IS) easily accessible with results processed within 2 weeks
    • Able to comply with strict follow-up in patients with MMR (MR3; BCR-ABL1≤0.1% IS) after TKI discontinuation: Molecular monitoring conducted monthly for 1 year, 6 weekly on the 2nd year, and 12 weekly thereafter
    • Can promptly resume TKI therapy (within 4 weeks) after loss of MMR with molecular monitoring 4-weekly until MMR is achieved, then 12-weekly monitoring thereafter
      • Perform BCR-ABL1 testing for patients who does not achieve MMR 3 months after resuming TKI therapy, and molecular monitoring should be conducted monthly for 6 months
    • Patient agrees to report any of the following:
      • Significant adverse events related to TKI therapy discontinuation
      • Disease phase progresses to accelerated or blast phase
      • MMR has not been achieved after resumption of treatment
  • Should only be considered in patients who are eligible for clinical trial
  • In patients with responsive disease, continuation of TKI therapy is recommended

Clinical Trials

  • Considerations for enrollment in clinical trials
    • In patients with AP-CML or BP-CML
    • In patients with treatment failure after Imatinib therapy
    • For patients with BCR-ABL1 transcripts >10% (IS) after initial treatment with 2nd-line TKIs at 3-month evaluation
    • For patients with BCR-ABL1 transcripts >10% (IS) or lack of partial cytogenetic response (PCyR) on bone marrow cytogenetics after initial treatment with 2nd-line TKIs at 6-month evaluation
    • For patients with cytogenic relapse, or less than PCyR or BCR-ABL1 transcripts >10% (IS) at 12-month evaluation

Pharmacotherapy

Targeted Cancer Therapy
First-generation Tyrosine Kinase Inhibitors (TKI)

Imatinib

  • Belongs to a class of signal transduction inhibitors (STIs) that interferes with the intracellular signaling pathways associated with malignancies
  • Inhibits the BCR-ABL1 tyrosine protein kinase in all phases of chronic myeloid leukemia
  • Recommended as 1st-line treatment for patients with chronic phase and advanced phase chronic myeloid leukemia
    • Several studies showed cytogenic response, hematologic response, decreased relapse and disease progression, and high overall survival in patients given Imatinib therapy

Second-generation TKI

Bosutinib

  • An oral multi-TKI that is used to treat adult patients with chronic phase, accelerated phase or blast phase Ph-positive (Ph+) chronic myeloid leukemia with resistance or intolerance to previous therapy (eg Imatinib, Dasatinib and Nilotinib)
  • Inhibits BCR-ABL1 kinase that promotes chronic myeloid leukemia and Src-family of kinases (eg Src, Lyn and Hck)
  • More potent for the BCR-ABL1 kinase than Imatinib
  • Not an efficient substrate for multidrug resistant transporters
  • Used for the management of cytogenetic or hematologic resistance to tyrosine kinase inhibitors and in patients with E255K/V, F317L/V/I/C, F359V/C/I, T315A, or Y253H mutations
  • At present, Bosutinib is not recommended as 1st-line therapy for patients newly diagnosed with chronic phase chronic myeloid leukemia

Dasatinib

  • An oral multi-TKI and is more potent in the inhibition of ABL than Imatinib
  • Inhibits Src tyrosine kinase, BCR-ABL and Imatinib-resistant mutations of BCR-ABL and binds to both active and inactive conformation of the ABL kinase domain
  • Recommended for all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy of Imatinib, Ph+ ALL with resistance or intolerance to prior therapy and in newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase
  • Preferred 1st-line treatment for patients with chronic phase chronic myeloid leukemia with intermediate- to high-risk score
    • Also preferred in patients with history of arrhythmia, heart disease, pancreatitis and hyperglycemia
  • Used for the management of cytogenetic or hematologic resistance to tyrosine kinase inhibitors and in patients with Y253H, E255K/V or F359V/C/I mutations

Nilotinib

  • Used for adult patients who are newly diagnosed with Ph+ chronic phase chronic myeloid leukemia
  • Also used to treat chronic and accelerated Ph+ chronic myeloid leukemia patients who are intolerant or resistant to a prior therapy that includes Imatinib
  • Preferred 1st-line treatment for patients with chronic phase chronic myeloid leukemia with intermediate- to high-risk score
  • Selectively inhibits the BCR-ABL1 tyrosine kinase and enhances the binding site affinity which makes Nilotinib 30 times more potent than Imatinib in Imatinib-sensitive chronic myeloid leukemia cell lines and 3-7 times more potent in Imatinib-resistant chronic myeloid leukemia cell lines
  • Used for the management of cytogenetic or hematologic resistance to tyrosine kinase inhibitors and in patients with F317L/V/I/C, T315A or V299L mutations

Ponatinib

  • An oral multi-kinase inhibitor that inhibits the ABL and T315l mutant ABL genes
  • Used for the treatment of T3151-positive CP-, AP-, or BP-CML or T315l-positive Ph+ALL and in patients with CP-, AP-, or BP-CML or Ph+ALL for patients when no other tyrosine kinase inhibitor is indicated

Management of TKI Therapy Toxicities

Imatinib

  • Chronic phase chronic myeloid leukemia with ANC <1.0 x 109/L and/or platelet count <50 x 109/L
    • Withhold therapy until ANC ≥1.5 x 109/L and/or platelet count ≥75 x 109/L, then resume at 400 mg initial dose, or 300 mg initial dose for recurrence
  • Accelerated and blast phase chronic myeloid leukemia with ANC <0.5 x 109/L and/or platelet count <10 x 109/L
    • Reduce dose to 400 mg if patient develops cytopenia unrelated to chronic myeloid leukemia
    • Reduce dose further to 300 mg if with persistent neutropenia after 2 weeks
    • Withhold Imatinib if still with cytopenia after 4 weeks, then resume at 300 mg dose if ANC ≥1.0 x 109/L and platelet count ≥20 x 109/L
  • Combination with growth factors may be considered for resistant neutropenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia
  • Withhold therapy if patient has bilirubin >3 x institutional ULN (IULN) or liver transaminases >5 x IULN
    • Resume therapy when bilirubin level is reduced to <1.5 x ULN and liver transaminases to <2.5 x IULN
  • Interrupt administration if any the following are present: Severe hepatotoxicity, severe fluid retention, rashes

Bosutinib

  • ANC <1.0 x 109/L or platelet count <50 x 109/L
    • Withhold treatment until ANC reaches ≥1.0 x 109/L and platelet count ≥50 x 109/L
    • May resume Bosutinib treatment when blood count returns to normal within 2 weeks
    • Reduce dose to 100 mg if blood counts remain low after 2 weeks; further dose reduction to 100 mg more may be considered for recurrence of cytopenia
  • Combination with growth factors may be considered for resistant neutropenia and thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia
  • Withhold therapy if patient's liver transaminases >5 x IULN
    • Resume therapy at 400 mg daily when liver transaminases are reduced to ≤2.5 x IULN
    • Discontinue Bosutinib if recovery takes longer than 4 weeks, or if with transaminase elevations >3 x IULN, bilirubin >2 x IULN, and alkaline phosphatase <2 x ULN
  • Withhold therapy if with grade 3-4 diarrhea, rashes, and other clinically significant, moderate, or severe non-hematologic toxicities until symptoms resolve
    • May resume treatment at 400 mg once daily when toxicity has resolved (ie diarrhea resolves to grade ≤1)

Dasatinib

  • Chronic phase chronic myeloid leukemia with ANC <0.5 x 109/L or platelet count <50 x 109/L
    • Withhold therapy until ANC ≥1.0 x 109/L and platelet count ≥50 x 109/L, if platelet count is <25 x 109/L, or for recurrence of ANC <0.5 x 109/L for 7 days
    • May resume treatment if blood count returns to normal after ≤7 days or at a reduced dose of 80 mg once daily for recurrence; reduce dose further to 50 mg once daily or discontinue treatment if at 3rd recurrence
  • Accelerated and blast phase chronic myeloid leukemia with ANC <0.5 x 109/L and/or platelet count <10 x 109/L
    • Withhold treatment if patient develops cytopenia unrelated to chronic myeloid leukemia, then resume at initial dose if with ANC ≥1.0 x 109/L and platelet count ≥20 x 109/L, or at a reduced dose of 100 mg/day if for recurrence, or at 80 mg once daily for 3rd recurrence 
  • Combination with growth factors may be considered for resistant neutropenia and thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia
  • Dasatinib should be discontinued permanently for confirmed presence of pulmonary arterial hypertension
  • Withhold therapy if with rashes and severe non-hematologic toxicities until symptoms resolve
    • May resume treatment at reduced dose depending on severity of adverse effect

Nilotinib

  • Monitor serum potassium and magnesium levels, ECG, glucose levels
  • Withhold treatment for any of the following:
    • ECG with QTc >480 msec
      • May resume treatment within 2 weeks at prior dose if with QTcF <450 msec and within 20 msec of baseline
      • May resume at reduced dose if QTcF between 450-480 msec after 2 weeks
      • Discontinue Nilotinib if QTcF returns to >480 msec after dose reduction
    • Chronic or accelerated phase, ANC <1.0 x 109/L and/or platelet count <50 x 109/L
    • Elevated serum lipase, amylase, bilirubin, or hepatic transaminases grade ≥3
  • Discontinue Nilotinib if with confirmed peripheral arterial occlusive disease
  • Combination with growth factors may be considered for resistant neutropenia and thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia

Ponatinib

  • Withhold treatment for any of the following:
    • ANC <1.0 x 109/L and/or platelet count <50 x 109/L
      • May resume therapy at initial dose (45 mg), at 30 mg if at 2nd occurrence, and at 15 mg if at 3rd occurrence when results are ANC ≥1.5 x 109/L and platelet count ≥75 x 109/L
    • Elevated serum lipase (symptomatic grade 1/2), amylase, bilirubin, or hepatic transaminases grade >3 x IULN (grade ≥2)
      • May resume treatment at reduced dose in patients with liver transaminase <3 x IULN, serum lipase <1.5 x ULN or ≤grade 1
    • Symptomatic grade 3 pancreatitis
      • Consider treatment resumption when serum lipase levels return to ≤grade 1 at a lower dose
    • Cerebral or GI hemorrhage, rashes, or fluid retention
  • Discontinue Ponatinib if patients receiving 15 mg doses present with liver transaminase of >3 x IULN, grade 4 symptomatic pancreatitis, and in patients with AST/ALT ≥3 x ULN plus bilirubin >2 x ULN and alkaline phosphatase <2 x ULN
  • Monitor for thromboembolism, cardiac function, and hepatic function
  • Combination with growth factors may be considered for resistant neutropenia and thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia

Cytotoxic Chemotherapy

Omacetaxine mepesuccinate

  • A cephalotaxine ester that inhibits protein synthesis by binding to the A-site located at the peptidyl-transferase center of the large ribosomal subunit and reduces the protein levels of BCR-ABL and myeloid leukemia cell 1 (MCL-1) that is independent of the direct BCR-ABL binding
  • Used to treat patients who have chronic phase chronic myeloid leukemia or accelerated phase chronic myeloid leukemia with disease progression that is resistant or intolerant to 2 or more tyrosine kinase inhibitors and for patients with T315I mutation
  • Reported adverse effects with Omacetaxine therapy include grade 3 or 4 hyperglycemia and CBC abnormalities
    • Delay treatment if patient presents with ANC <0.5 x 109/L or platelet count <50 x 109/L
    • May resume at reduced dose every 2 days for the next cycle if with ANC ≥1.0 x 109/L and platelet count ≥50 x 109/L

Hydroxyurea

  • An antimetabolite that rapidly reduces high white blood cell counts
  • Inhibits the ribonucleotide reductase and DNA synthesis and does not interfere with protein or RNA synthesis
  • Treatment option for symptomatic leukocytosis or thrombocytosis awaiting confirmation of BCR-ABL1
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).